HFHajra Fayyaz

Hajra Fayyaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hajra Fayyaz has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Imran Ullah

    Division of Applied Life Science (BK21 Four), Gyeongsang National University, Jinju 52828, Gyeongnam Province, Republic of Korea

    2 shared publications
  • Aamir Sohail

    Department of Biochemistry , Faculty of Biological Sciences , Quaid-i-Azam University , Islamabad , Pakistan , qau.edu.pk

    1 shared publication
  • Ali Faheem

    Department of Biochemistry, Sanquan College of Xinxiang Medical University, Xinxiang, China

    1 shared publication
  • Amany I. Almars

    Department of Medical Laboratory Sciences, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia

    1 shared publication
  • Atteaya Zaman

    1 shared publication
  • Hailah M. Almohaimeed

    Department of Basic Science, College of Medicine, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia

    1 shared publication

Latest Publications

  • Open Access

    Immunosuppression in Infectious Diseases: Causes and Effects

    by Hajra Fayyaz, Atteaya Zaman, Imran Ullah, Waheed Rafiq, Muhammad Hasnain Murtaza

    Immunosuppression is the reduction in the normal immune system. This suppression weakens the activation and functioning of the immune system, making individuals more susceptible to infections. By understanding immunosuppression, the recognition, management, and treatment of infectious diseases can be achieved. Generally, immunosuppression is associated with the outcome of a disease (primary or secondary immunodeficiencies). Currently, a large population is facing immunosuppression due to the exposure of therapeutic drugs. These medications modulate the immune system and effectively manage immune-related diseases, but they also increase the chance of infections. The clinical picture of infectious diseases in immune-suppressed individuals differs from the immune-competent, making the diagnosis challenging. Therefore, recognition and management of immunosuppression are necessary for preventing and curing the affected population. Herein, we will discuss an overview of immunosuppression and its role in infectious diseases, how immune cells and molecules work together to combat pathogens, the causes of immunosuppression (particularly primary immunodeficiency), and its clinical, diagnostic, and effects on human health.


  • Exome sequencing revealed variants in SGCA and SIL1 genes underlying limb girdle muscular dystrophy and Marinesco–Sjögren syndrome patients

    by Ali Faheem, Rizwan Masud, Rabea Nasir, Zeeshan Khalid Awan, Hammad Ali Nasir, Zara Khalid Khan, Hajra Fayyaz, Syed Irfan Raza

    Background Inherited neuromuscular (NMD) and neurodegenerative diseases (NDD) belong to two distinct categories that disturb different components of the nervous system, leading to a variety of different symptoms and clinical manifestations. Both NMD and NDD are a heterogeneous group of genetic conditions. Genetic variations in the SGCA and SIL1 genes have been implicated in causing Limb Girdle Muscular Dystrophy (LGMD), a type of neuromuscular disorder, and Marinesco–Sjögren Syndrome (MSS) which is a neurodegenerative disorder. Methods In the present study, we have investigated four patients presenting LGMD and five patients with MSS features. After collecting detailed clinical and family history, necessary laboratory investigations, including estimation of a skeletal muscle marker enzyme serum creatine kinase (CK), nerve conduction study (NCS), electromyography (EMG), echocardiography (Echo), Magnetic resonance imaging (MRI –brain), CT-brain and X-rays were performed. Whole exome followed by Sanger sequencing was employed to search for the disease-causing variants. Results Physical examination in LGMD patients revealed poor muscle tone and facing difficulty in straightening up from the floor. Clinical history revealed frequent falls and strenuousness in climbing stairs. They started toe-walking in early childhood. Laboratory investigations confirmed elevated CK levels and abnormal NCS and EMG. The MSS patients showed abnormalities in gate and jerking movement, abnormal speech, and strabismus with cataract. MRI-brain showed cerebral atrophy in some MSS patients with elevated CK levels. Whole exome sequencing revealed a nonsense variant [c.C574T, p.(Arg192*)] in the SGCA gene and a frameshift [c.936dupG, p.(Leu313AlaFs*39)] in the SIL1 gene in LGMD and MSS patients, respectively. Conclusion Our study emphasizes the significance of integrating clinical and genetic analyses for precise diagnosis and tailored management strategies in inherited NMD and NDD disorders. To the best of our knowledge, this is the first study documenting SGCA and SIL1 recurrent variants in subcontinent populations with few rare clinical features. The recurrent mutations expanding the global understanding of the mutation’s geographic and ethnic distribution and contributing valuable epidemiological data. The study will facilitate genetic counseling for families experiencing similar clinical features, both within Pakistani populations and in other regions.


  • Open Access

    Viscosol Treatment Ameliorates Insulin‐Mediated Regulation of Dyslipidemia, Hepatic Steatosis, and Lipid Metabolism by Targeting PTP1B in Type‐2 Diabetic Mice Model

    by Idrees Raza, Aamir Sohail, Hamza Muneer, Hajra Fayyaz, Zia Uddin, Amany I. Almars, Waheeb S. Aggad, Hailah M. Almohaimeed, Imran Ullah

    Type 2 diabetes mellitus (T2DM), a metabolic disorder, has the hallmarks of persistent hyperglycemia, insulin resistance, and dyslipidemia. Protein‐tyrosine phosphatase 1B (PTP1B) was found to be overexpressed in many tissues in the case of T2DM and involved in the negative regulation of insulin signaling. So, PTP1B inhibition can act as a therapeutic target for T2DM. Numerous studies claimed the anti‐inflammatory, hypoglycemic, hepatoprotective, and hypolipidemic activities of Dodonaea viscosa. Previously, we generated the high‐fat diet (HFD)‐low dose streptozotocin (STZ)–induced diabetic male mice model and treated it with a PTP1B inhibitor (5, 7‐dihydroxy‐3, 6‐dimethoxy‐2‐ (4‐methoxy‐3‐ (3‐methyl‐2‐enyl) phenyl)‐4H‐chromen‐4‐one), isolated from Dodonaea viscosa. In the current study, we aimed to investigate the De novo lipogenesis, adipocyte differentiation, augmentation of lipoproteins clearance, fatty acid uptake, antilipolysis activity, and hepatic steatosis of PTP1B inhibition in adipose and liver tissues of the HFD‐STZ–induced diabetic mice model. We found the retrieval of normal morphology of adipocytes and hepatocytes in the compound‐treated group. The biochemical parameters showed the gradual reduction of LDL, VLDL, TC, and TG in the serum of the compound‐treated group. To further test our hypothesis, real‐time PCR was performed, and data revealed the reduction of PTP1B and other inflammatory markers in both tissues, showing enhanced expression of insulin signaling markers (INSR, IRS1, IRS2, and PI3K). Our compound upregulated the adipogenic (PPARγ), lipogenic (SREBP1c, FAS, ACC, and DGAT2), lipoprotein clearance (LPL, LDLR, and VLDLR), fatty acid uptake (CD36 and FATP1), and lipid droplet forming (FSP27 and perilipin‐1) markers expressions in adipocytes and downregulated in hepatocytes. Furthermore, we found elevated cholesterol efflux (in adipose and liver) and decreased lipolysis in adipocytes and elevated in hepatocytes. Hence, we can conclude that our compound protects the adipocytes from abrupt lipolysis and stimulates adipocyte differentiation. In addition, it plays a hepatic protective role by shifting clearance and uptake of lipoproteins and fatty acids to the peripheral tissues and retrieving the fatty liver condition.